NASDAQ:ABEO Abeona Therapeutics (ABEO) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free ABEO Stock Alerts $7.25 -0.09 (-1.23%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$7.10▼$7.4650-Day Range$4.07▼$8.6852-Week Range$2.65▼$9.01Volume267,314 shsAverage Volume345,842 shsMarket Capitalization$198.29 millionP/E RatioN/ADividend YieldN/APrice Target$38.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainabilityStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaSustainability Get Abeona Therapeutics alerts: Email Address Abeona Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside424.1% Upside$38.00 Price TargetShort InterestBearish6.60% of Float Sold ShortDividend StrengthN/ASustainability-1.03Upright™ Environmental ScoreNews Sentiment0.02Based on 7 Articles This WeekInsider TradingSelling Shares$36,199 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.83) to ($1.55) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.14 out of 5 starsMedical Sector197th out of 938 stocksPharmaceutical Preparations Industry87th out of 441 stocks 3.5 Analyst's Opinion Consensus RatingAbeona Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $38.00, Abeona Therapeutics has a forecasted upside of 424.1% from its current price of $7.25.Amount of Analyst CoverageAbeona Therapeutics has received no research coverage in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted6.60% of the float of Abeona Therapeutics has been sold short.Short Interest Ratio / Days to CoverAbeona Therapeutics has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Abeona Therapeutics has recently increased by 3.66%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAbeona Therapeutics does not currently pay a dividend.Dividend GrowthAbeona Therapeutics does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAbeona Therapeutics has received a 69.10% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases ", "Clinical research services for genetic diseases", and "Preclinical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Abeona Therapeutics is -1.03. Previous Next 2.8 News and Social Media Coverage News SentimentAbeona Therapeutics has a news sentiment score of 0.02. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Abeona Therapeutics this week, compared to 2 articles on an average week.Search Interest14 people have searched for ABEO on MarketBeat in the last 30 days. This is an increase of 27% compared to the previous 30 days.MarketBeat Follows11 people have added Abeona Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 83% compared to the previous 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Abeona Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $36,199.00 in company stock.Percentage Held by InsidersOnly 5.30% of the stock of Abeona Therapeutics is held by insiders.Percentage Held by Institutions80.56% of the stock of Abeona Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Abeona Therapeutics are expected to grow in the coming year, from ($1.83) to ($1.55) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Abeona Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Abeona Therapeutics is -2.81, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAbeona Therapeutics has a P/B Ratio of 12.08. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsCentral Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.Find out how you can protect yourself now >>> About Abeona Therapeutics Stock (NASDAQ:ABEO)Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B. It is also developing ABO-201 gene therapy for juvenile Batten disease; ABO-202 gene therapy for treatment of infantile Batten disease; EB-201 for for epidermolysis bullosa (EB); ABO-301 for Fanconi anemia disorder; and ABO-302 using a novel CRISPR/Cas9-based gene editing approach to gene therapy program for rare blood diseases. Further, it is involved in marketing MuGard, a mucoadhesive oral wound rinse for the management of mucositis, stomatitis, aphthous ulcers, and traumatic ulcers. Abeona Therapeutics Inc. has collaborations with EB Research Partnership and Epidermolysis Bullosa Medical Research Foundation that focus on gene therapy treatments for EB; and Brammer Bio for commercial translation of ABO-102. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015. Abeona Therapeutics Inc. was incorporated in 1989 and is based in Dallas, Texas.Read More ABEO Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ABEO Stock News HeadlinesMarch 27, 2024 | finance.yahoo.comHere's Why We're Not Too Worried About Abeona Therapeutics' (NASDAQ:ABEO) Cash Burn SituationMarch 23, 2024 | americanbankingnews.comAnalysts Set Expectations for Abeona Therapeutics Inc's FY2024 Earnings (NASDAQ:ABEO)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | investorplace.comABEO Stock Earnings: Abeona Therapeutics Misses EPS for Q4 2023March 19, 2024 | finance.yahoo.comQ4 2023 Abeona Therapeutics Inc Earnings CallMarch 19, 2024 | finance.yahoo.comAbeona Therapeutics Inc (ABEO) Reports Full Year 2023 Financial ResultsMarch 18, 2024 | msn.comInventiva Phase 2 study for MASH drug meets primary endpointMarch 18, 2024 | marketwatch.comAbeona Therapeutics Shares Drop 13% After FDA Inspection of Cleveland FacilityMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 18, 2024 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsMarch 18, 2024 | msn.comAbeona Therapeutics GAAP EPS of -$2.53, revenue of $3.5MMarch 18, 2024 | globenewswire.comAbeona Therapeutics Reports Full Year 2023 Financial Results and Announces Completion of FDA InspectionsMarch 16, 2024 | finance.yahoo.comABEO Dec 2024 15.000 callMarch 10, 2024 | fool.comAbeona Therapeutics (NASDAQ: ABEO)March 10, 2024 | finance.yahoo.comSeveral Insiders Invested In Abeona Therapeutics Flagging Positive NewsMarch 5, 2024 | globenewswire.comAbeona Therapeutics Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)February 22, 2024 | benzinga.comAbeona Therapeutics Stock (NASDAQ:ABEO), Short Interest ReportFebruary 21, 2024 | benzinga.comAbeona Therapeutics Stock (NASDAQ:ABEO) Insider TradesFebruary 20, 2024 | money.usnews.comAbeona Therapeutics IncFebruary 19, 2024 | finance.yahoo.comABEO Apr 2024 7.500 callFebruary 16, 2024 | finance.yahoo.comABEO Mar 2024 10.000 callFebruary 16, 2024 | investing.comAbeona Therapeutics Inc (ABEO)February 15, 2024 | finance.yahoo.comSteven Cohen's Firm Increases Stake in Abeona Therapeutics IncFebruary 12, 2024 | finance.yahoo.comIndividual investors in Abeona Therapeutics Inc. (NASDAQ:ABEO) are its biggest bettors, and their bets paid off as stock gained 45% last weekFebruary 3, 2024 | finanznachrichten.deAbeona Therapeutics Inc.: Abeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)February 1, 2024 | finance.yahoo.comABEO: FDA BIMO Inspection and BLA Mid-Cycle Review Complete…February 1, 2024 | finance.yahoo.comAbeona Therapeutics Announces Progress Update on Pz-cel Biologics License Application (BLA)See More Headlines Receive ABEO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Abeona Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/15/2021Today3/29/2024Next Earnings (Estimated)5/09/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:ABEO Previous SymbolOTCMKTS:ACCP CUSIPN/A CIK318306 Webwww.abeonatherapeutics.com Phone214-665-9495Fax214-905-5101EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$38.00 High Stock Price Target$38.00 Low Stock Price Target$38.00 Potential Upside/Downside+424.1%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($2.58) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-54,190,000.00 Net MarginsN/A Pretax Margin-1,548.23% Return on Equity-280.58% Return on Assets-76.90% Debt Debt-to-Equity RatioN/A Current Ratio4.15 Quick Ratio4.15 Sales & Book Value Annual Sales$3.50 million Price / Sales56.65 Cash FlowN/A Price / Cash FlowN/A Book Value$0.60 per share Price / Book12.08Miscellaneous Outstanding Shares27,350,000Free Float25,905,000Market Cap$198.29 million OptionableOptionable Beta1.49 (Almost) Everything You Need To Know About The EV MarketClick the link below and we'll send you MarketBeat's guide to investing in electric vehicle technologies (EV) and which EV stocks show the most promise. Get This Free Report Key ExecutivesMr. Steven H. Rouhandeh (Age 61)Exec. Chairman Dr. Timothy J. Miller (Age 46)Pres, Chief Scientific Officer & Director Mr. Jeffrey Blaine Davis (Age 55)Chief Operating Officer Mr. Carsten Thiel (Age 54)Chief Exec. Officer Mr. Stephen B. Thompson (Age 64)Sr. VP of Fin. and Admin., Chief Accounting Officer, Sec. & Treasurer Key CompetitorsDesign TherapeuticsNASDAQ:DSGNIncannex HealthcareNASDAQ:IXHLAlimera SciencesNASDAQ:ALIMCapricor TherapeuticsNASDAQ:CAPRInventivaNASDAQ:IVAView All CompetitorsInsiders & InstitutionsVanguard Group Inc.Bought 348,196 shares on 3/11/2024Ownership: 4.445%Vanguard Group Inc.Bought 348,196 shares on 2/15/2024Ownership: 4.445%Barclays PLCSold 201,544 shares on 2/15/2024Ownership: 0.685%Citadel Advisors LLCBought 8,600 shares on 2/15/2024Ownership: 0.000%Point72 Asset Management L.P.Sold 420,200 shares on 2/14/2024Ownership: 3.072%View All Insider TransactionsView All Institutional Transactions ABEO Stock Analysis - Frequently Asked Questions Should I buy or sell Abeona Therapeutics stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Abeona Therapeutics in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ABEO shares. View ABEO analyst ratings or view top-rated stocks. What is Abeona Therapeutics' stock price target for 2024? 1 analysts have issued 1-year target prices for Abeona Therapeutics' stock. Their ABEO share price targets range from $38.00 to $38.00. On average, they anticipate the company's share price to reach $38.00 in the next twelve months. This suggests a possible upside of 424.1% from the stock's current price. View analysts price targets for ABEO or view top-rated stocks among Wall Street analysts. How have ABEO shares performed in 2024? Abeona Therapeutics' stock was trading at $5.01 at the start of the year. Since then, ABEO shares have increased by 44.7% and is now trading at $7.25. View the best growth stocks for 2024 here. When is Abeona Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024. View our ABEO earnings forecast. How were Abeona Therapeutics' earnings last quarter? Abeona Therapeutics Inc (NASDAQ:ABEO) issued its earnings results on Monday, November, 15th. The biopharmaceutical company reported ($4.00) earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of ($4.00). When did Abeona Therapeutics' stock split? Abeona Therapeutics's stock reverse split on Tuesday, July 5th 2022. The 1-25 reverse split was announced on Tuesday, July 5th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, July 5th 2022. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. What other stocks do shareholders of Abeona Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Abeona Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), Corbus Pharmaceuticals (CRBP), OPKO Health (OPK), Sangamo Therapeutics (SGMO), Energy Transfer (ET), Sorrento Therapeutics (SRNE), Micron Technology (MU), TherapeuticsMD (TXMD), VBI Vaccines (VBIV) and Advanced Micro Devices (AMD). Who are Abeona Therapeutics' major shareholders? Abeona Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (4.45%), Vanguard Group Inc. (4.45%), AIGH Capital Management LLC (3.18%), Point72 Asset Management L.P. (3.07%), Worth Venture Partners LLC (0.79%) and Barclays PLC (0.69%). Insiders that own company stock include Brendan M O'malley, Christine Berni Silverstein, Edward Carr, Joseph Walter Vazzano, Mark Alvino, Michael Amoroso, Todd Wider and Vishwas Seshadri. View institutional ownership trends. How do I buy shares of Abeona Therapeutics? Shares of ABEO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ABEO) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyFed launches fourth dollar overhaulStansberry Research Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Abeona Therapeutics Inc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.